These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29930748)

  • 21. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
    Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
    Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
    Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
    J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
    Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
    Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
    Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
    Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
    McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
    Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
    Gussen H; Hohlstein P; Bartneck M; Warzecha KT; Buendgens L; Luedde T; Trautwein C; Koch A; Tacke F
    J Intensive Care; 2019; 7():26. PubMed ID: 31061709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia.
    Mölkänen T; Ruotsalainen E; Thorball CW; Järvinen A
    Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1417-24. PubMed ID: 21479972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
    Usnarska-Zubkiewicz L; Strutyńska-Karpińska M; Zubkiewicz-Kucharska A; Zarębski P; Grabowski K
    Adv Clin Exp Med; 2014; 23(6):959-67. PubMed ID: 25618124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
    Indumati V; Vijay V; Krishnaswamy D; Rajeshwari V; Ramesh A; Shantala D; Shilpa A
    Indian J Tuberc; 2017 Jul; 64(3):206-211. PubMed ID: 28709490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
    Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
    Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
    Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
    Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of suPAR and hsCRP on acute kidney injury after cardiac surgery.
    Rasmussen SR; Nielsen RV; Møgelvang R; Ostrowski SR; Ravn HB
    BMC Nephrol; 2021 Apr; 22(1):120. PubMed ID: 33827466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
    Guo H; Zhou LX; Ma H; Liu B; Cheng J; Ma YY; Zhao L
    Oncol Lett; 2017 Jul; 14(1):383-389. PubMed ID: 28693180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
    Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
    World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.